We next examined whether human ccRCC tumours with similar genomic characteristics (VHL inactivation; VHL inactivation and MYC activation; and VHL inactivation, CDKN2A loss and MYC activation) have similar outcomes as those seen in our mouse models. This evidence concerns the gene MYC and neoplasm.